Fig. 2From: Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancerClinical relevance of therapeutic changes due to discordance in molecular surrogate subtypes in the largest tumor (PT1) and the second tumor (PT2) in 11 of 180 patients with ipsilateral multifocal primary breast cancer that were surgically treated at Sahlgrenska University Hospital (Gothenburg, Sweden) between 2012 and 2017Back to article page